Search
Auranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalIt has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression
Aurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnAurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression...
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalCasimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118] … However, the specific mutations, and hence the precise exon skipping, targeted by each is different.
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigational[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedAn advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]